Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis
Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid. To the Editor: Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are an increasing p...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2015-11, Vol.373 (20), p.1986-1988 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1988 |
|---|---|
| container_issue | 20 |
| container_start_page | 1986 |
| container_title | The New England journal of medicine |
| container_volume | 373 |
| creator | Bloemberg, Guido V Keller, Peter M Stuckia, David Trauner, Andrej Borrell, Sonia Latshang, Tsogyal Coscolla, Mireia Rothe, Thomas Hömke, Rico Ritter, Claudia Feldmann, Julia Schulthess, Bettina Gagneux, Sebastien Böttger, Erik C |
| description | Treatment of multidrug-resistant
Mycobacterium tuberculosis
is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
To the Editor:
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are an increasing public health threat.
1
Bedaquiline and delamanid are two drugs that were recently approved by the Food and Drug Administration for treatment of MDR-TB and XDR-TB.
2
Here we describe the stepwise amplification of drug resistance in a patient who had emigrated from Tibet to Switzerland in December 2010 and who presented to a Swiss hospital with preextensively drug-resistant tuberculosis at that time.
Genome sequencing revealed that the initial
Mycobacterium tuberculosis
isolate harbored nine mutations in genes associated with resistance to seven drugs (Figure 1, and the Supplementary Appendix, . . . |
| doi_str_mv | 10.1056/NEJMc1505196 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1732853895</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3865118141</sourcerecordid><originalsourceid>FETCH-LOGICAL-m804-cf8c6805ab23b390a698857e5b7f03baae2d2cc03274bb80fb0aad4d5dfab07f3</originalsourceid><addsrcrecordid>eNpNkEtPwzAQhC0EoqVw44wswTWwju3EPpZSXiogodyt9SMiVR6t0xz67wmiSOxlDvvNrmYIuWRwy0Bmd-_L1zfHJEimsyMyZZLzRAjIjskUIFWJyDWfkLO-X8M4TOhTMkkzKbXUYkpWc7cdqhg8_Qx91e-wdYHuOnofPI6LumoDxdbTh1Bjg23ladXS4itE3Oxp2UVaDDZEN9Td6D4nJyXWfbg46IwUj8ti8ZysPp5eFvNV0igQiSuVyxRItCm3XANmWimZB2nzErhFDKlPnQOe5sJaBaUFRC-89CVayEs-I9e_Zzex2w6h35l1N8R2_GhYzlMludJypK4O1GCb4M0mVg3GvfnLPgI3v0DT9KYN68YwMD-Vmv-V8m9XJWXi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1732853895</pqid></control><display><type>article</type><title>Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Bloemberg, Guido V ; Keller, Peter M ; Stuckia, David ; Trauner, Andrej ; Borrell, Sonia ; Latshang, Tsogyal ; Coscolla, Mireia ; Rothe, Thomas ; Hömke, Rico ; Ritter, Claudia ; Feldmann, Julia ; Schulthess, Bettina ; Gagneux, Sebastien ; Böttger, Erik C</creator><creatorcontrib>Bloemberg, Guido V ; Keller, Peter M ; Stuckia, David ; Trauner, Andrej ; Borrell, Sonia ; Latshang, Tsogyal ; Coscolla, Mireia ; Rothe, Thomas ; Hömke, Rico ; Ritter, Claudia ; Feldmann, Julia ; Schulthess, Bettina ; Gagneux, Sebastien ; Böttger, Erik C</creatorcontrib><description>Treatment of multidrug-resistant
Mycobacterium tuberculosis
is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
To the Editor:
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are an increasing public health threat.
1
Bedaquiline and delamanid are two drugs that were recently approved by the Food and Drug Administration for treatment of MDR-TB and XDR-TB.
2
Here we describe the stepwise amplification of drug resistance in a patient who had emigrated from Tibet to Switzerland in December 2010 and who presented to a Swiss hospital with preextensively drug-resistant tuberculosis at that time.
Genome sequencing revealed that the initial
Mycobacterium tuberculosis
isolate harbored nine mutations in genes associated with resistance to seven drugs (Figure 1, and the Supplementary Appendix, . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1505196</identifier><identifier>PMID: 26559594</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antitubercular Agents - therapeutic use ; Diarylquinolines - therapeutic use ; Drug resistance ; Drug Resistance, Bacterial - genetics ; Drug Therapy, Combination ; Genomes ; Humans ; Male ; Multidrug resistance ; Mutation ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - genetics ; Nitroimidazoles - therapeutic use ; Oxazoles - therapeutic use ; Public health ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy</subject><ispartof>The New England journal of medicine, 2015-11, Vol.373 (20), p.1986-1988</ispartof><rights>Copyright © 2015 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1505196$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1732853895?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2760,26103,27924,27925,52382,54064,64385,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26559594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bloemberg, Guido V</creatorcontrib><creatorcontrib>Keller, Peter M</creatorcontrib><creatorcontrib>Stuckia, David</creatorcontrib><creatorcontrib>Trauner, Andrej</creatorcontrib><creatorcontrib>Borrell, Sonia</creatorcontrib><creatorcontrib>Latshang, Tsogyal</creatorcontrib><creatorcontrib>Coscolla, Mireia</creatorcontrib><creatorcontrib>Rothe, Thomas</creatorcontrib><creatorcontrib>Hömke, Rico</creatorcontrib><creatorcontrib>Ritter, Claudia</creatorcontrib><creatorcontrib>Feldmann, Julia</creatorcontrib><creatorcontrib>Schulthess, Bettina</creatorcontrib><creatorcontrib>Gagneux, Sebastien</creatorcontrib><creatorcontrib>Böttger, Erik C</creatorcontrib><title>Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Treatment of multidrug-resistant
Mycobacterium tuberculosis
is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
To the Editor:
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are an increasing public health threat.
1
Bedaquiline and delamanid are two drugs that were recently approved by the Food and Drug Administration for treatment of MDR-TB and XDR-TB.
2
Here we describe the stepwise amplification of drug resistance in a patient who had emigrated from Tibet to Switzerland in December 2010 and who presented to a Swiss hospital with preextensively drug-resistant tuberculosis at that time.
Genome sequencing revealed that the initial
Mycobacterium tuberculosis
isolate harbored nine mutations in genes associated with resistance to seven drugs (Figure 1, and the Supplementary Appendix, . . .</description><subject>Antitubercular Agents - therapeutic use</subject><subject>Diarylquinolines - therapeutic use</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial - genetics</subject><subject>Drug Therapy, Combination</subject><subject>Genomes</subject><subject>Humans</subject><subject>Male</subject><subject>Multidrug resistance</subject><subject>Mutation</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - genetics</subject><subject>Nitroimidazoles - therapeutic use</subject><subject>Oxazoles - therapeutic use</subject><subject>Public health</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpNkEtPwzAQhC0EoqVw44wswTWwju3EPpZSXiogodyt9SMiVR6t0xz67wmiSOxlDvvNrmYIuWRwy0Bmd-_L1zfHJEimsyMyZZLzRAjIjskUIFWJyDWfkLO-X8M4TOhTMkkzKbXUYkpWc7cdqhg8_Qx91e-wdYHuOnofPI6LumoDxdbTh1Bjg23ladXS4itE3Oxp2UVaDDZEN9Td6D4nJyXWfbg46IwUj8ti8ZysPp5eFvNV0igQiSuVyxRItCm3XANmWimZB2nzErhFDKlPnQOe5sJaBaUFRC-89CVayEs-I9e_Zzex2w6h35l1N8R2_GhYzlMludJypK4O1GCb4M0mVg3GvfnLPgI3v0DT9KYN68YwMD-Vmv-V8m9XJWXi</recordid><startdate>20151112</startdate><enddate>20151112</enddate><creator>Bloemberg, Guido V</creator><creator>Keller, Peter M</creator><creator>Stuckia, David</creator><creator>Trauner, Andrej</creator><creator>Borrell, Sonia</creator><creator>Latshang, Tsogyal</creator><creator>Coscolla, Mireia</creator><creator>Rothe, Thomas</creator><creator>Hömke, Rico</creator><creator>Ritter, Claudia</creator><creator>Feldmann, Julia</creator><creator>Schulthess, Bettina</creator><creator>Gagneux, Sebastien</creator><creator>Böttger, Erik C</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20151112</creationdate><title>Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis</title><author>Bloemberg, Guido V ; Keller, Peter M ; Stuckia, David ; Trauner, Andrej ; Borrell, Sonia ; Latshang, Tsogyal ; Coscolla, Mireia ; Rothe, Thomas ; Hömke, Rico ; Ritter, Claudia ; Feldmann, Julia ; Schulthess, Bettina ; Gagneux, Sebastien ; Böttger, Erik C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-m804-cf8c6805ab23b390a698857e5b7f03baae2d2cc03274bb80fb0aad4d5dfab07f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antitubercular Agents - therapeutic use</topic><topic>Diarylquinolines - therapeutic use</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial - genetics</topic><topic>Drug Therapy, Combination</topic><topic>Genomes</topic><topic>Humans</topic><topic>Male</topic><topic>Multidrug resistance</topic><topic>Mutation</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - genetics</topic><topic>Nitroimidazoles - therapeutic use</topic><topic>Oxazoles - therapeutic use</topic><topic>Public health</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bloemberg, Guido V</creatorcontrib><creatorcontrib>Keller, Peter M</creatorcontrib><creatorcontrib>Stuckia, David</creatorcontrib><creatorcontrib>Trauner, Andrej</creatorcontrib><creatorcontrib>Borrell, Sonia</creatorcontrib><creatorcontrib>Latshang, Tsogyal</creatorcontrib><creatorcontrib>Coscolla, Mireia</creatorcontrib><creatorcontrib>Rothe, Thomas</creatorcontrib><creatorcontrib>Hömke, Rico</creatorcontrib><creatorcontrib>Ritter, Claudia</creatorcontrib><creatorcontrib>Feldmann, Julia</creatorcontrib><creatorcontrib>Schulthess, Bettina</creatorcontrib><creatorcontrib>Gagneux, Sebastien</creatorcontrib><creatorcontrib>Böttger, Erik C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bloemberg, Guido V</au><au>Keller, Peter M</au><au>Stuckia, David</au><au>Trauner, Andrej</au><au>Borrell, Sonia</au><au>Latshang, Tsogyal</au><au>Coscolla, Mireia</au><au>Rothe, Thomas</au><au>Hömke, Rico</au><au>Ritter, Claudia</au><au>Feldmann, Julia</au><au>Schulthess, Bettina</au><au>Gagneux, Sebastien</au><au>Böttger, Erik C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2015-11-12</date><risdate>2015</risdate><volume>373</volume><issue>20</issue><spage>1986</spage><epage>1988</epage><pages>1986-1988</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Treatment of multidrug-resistant
Mycobacterium tuberculosis
is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
To the Editor:
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are an increasing public health threat.
1
Bedaquiline and delamanid are two drugs that were recently approved by the Food and Drug Administration for treatment of MDR-TB and XDR-TB.
2
Here we describe the stepwise amplification of drug resistance in a patient who had emigrated from Tibet to Switzerland in December 2010 and who presented to a Swiss hospital with preextensively drug-resistant tuberculosis at that time.
Genome sequencing revealed that the initial
Mycobacterium tuberculosis
isolate harbored nine mutations in genes associated with resistance to seven drugs (Figure 1, and the Supplementary Appendix, . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>26559594</pmid><doi>10.1056/NEJMc1505196</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2015-11, Vol.373 (20), p.1986-1988 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_1732853895 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antitubercular Agents - therapeutic use Diarylquinolines - therapeutic use Drug resistance Drug Resistance, Bacterial - genetics Drug Therapy, Combination Genomes Humans Male Multidrug resistance Mutation Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - genetics Nitroimidazoles - therapeutic use Oxazoles - therapeutic use Public health Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy |
| title | Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T08%3A04%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acquired%20Resistance%20to%20Bedaquiline%20and%20Delamanid%20in%20Therapy%20for%20Tuberculosis&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Bloemberg,%20Guido%20V&rft.date=2015-11-12&rft.volume=373&rft.issue=20&rft.spage=1986&rft.epage=1988&rft.pages=1986-1988&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1505196&rft_dat=%3Cproquest_pubme%3E3865118141%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1732853895&rft_id=info:pmid/26559594&rfr_iscdi=true |